Ledyard National Bank Has $379,000 Stake in Novo Nordisk A/S (NYSE:NVO)

Ledyard National Bank decreased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 95.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,338 shares of the company’s stock after selling 145,370 shares during the period. Ledyard National Bank’s holdings in Novo Nordisk A/S were worth $379,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Advisors Preferred LLC acquired a new stake in shares of Novo Nordisk A/S in the second quarter valued at approximately $26,000. Valeo Financial Advisors LLC increased its holdings in shares of Novo Nordisk A/S by 510.7% in the second quarter. Valeo Financial Advisors LLC now owns 629 shares of the company’s stock valued at $32,000 after purchasing an additional 526 shares in the last quarter. Wealthcare Advisory Partners LLC increased its holdings in shares of Novo Nordisk A/S by 75.6% in the second quarter. Wealthcare Advisory Partners LLC now owns 864 shares of the company’s stock valued at $44,000 after purchasing an additional 372 shares in the last quarter. Mirova acquired a new stake in shares of Novo Nordisk A/S in the second quarter valued at approximately $49,000. Finally, Doyle Wealth Management acquired a new stake in shares of Novo Nordisk A/S in the second quarter valued at approximately $57,000. 7.34% of the stock is owned by institutional investors.

A number of brokerages recently weighed in on NVO. ValuEngine lowered shares of Novo Nordisk A/S from a “sell” rating to a “strong sell” rating in a report on Saturday, October 5th. Citigroup raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 17th. Bank of America raised their price target on shares of Novo Nordisk A/S from $355.00 to $400.00 and gave the company a “neutral” rating in a report on Friday, September 13th. Zacks Investment Research raised shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 price target for the company in a report on Monday, July 15th. Finally, Jefferies Financial Group lowered shares of Novo Nordisk A/S from a “hold” rating to an “underperform” rating in a report on Friday, August 30th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the company. Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus target price of $159.65.

Shares of NVO stock opened at $54.32 on Friday. Novo Nordisk A/S has a 52-week low of $41.59 and a 52-week high of $54.37. The stock has a market cap of $126.69 billion, a PE ratio of 22.39, a PEG ratio of 2.24 and a beta of 0.58. The company has a debt-to-equity ratio of 0.06, a quick ratio of 0.73 and a current ratio of 1.04. The firm’s 50 day moving average price is $51.79 and its two-hundred day moving average price is $50.17.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Friday, August 9th. The company reported $0.61 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.61. Novo Nordisk A/S had a net margin of 32.16% and a return on equity of 75.16%. The firm had revenue of $4.52 billion for the quarter, compared to analysts’ expectations of $4.41 billion. As a group, sell-side analysts predict that Novo Nordisk A/S will post 2.43 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Read More: What is an overbought condition?

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.